Divis Laboratories

6,922.50
+34.00
(0.49%)
Market Cap
1,83,770.62 Cr
EPS
82.53
PE Ratio
83.40
Dividend Yield
0.44 %
Industry
Healthcare
52 Week High
6,945.00
52 Week Low
4,395.30
PB Ratio
12.21
Debt to Equity
0.00
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from24 analysts
SELL
Analysts have suggested that investors can sell this stock
Buy
Buy+33.33 %
+33.33 %
Hold
Hold+25.00 %
+25.00 %
Sell
Sell+41.67 %
+41.67 %
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,654.80
#1 3,97,041.95
35.18
#1 54,729.00
12.06
#1 10,980
-18.99
48.33
6,922.50
#2 1,83,770.62
#10 83.40
#9 9,360.00
#10 0.89
#7 2,117
#4 23.05
68.54
1,483.30
1,19,807.30
23.71
28,409.50
7.12
5,291
30.28
54.26
3,313.70
1,12,150.67
59.20
11,539.40
11.59
1,911
10.91
62.08
1,276.20
1,06,507.96
#1 19.71
33,741.20
12.36
5,725
21.14
54.13
2,420.00
99,880.36
50.14
12,207.40
19.57
1,925
-10.91
59.65
970.45
97,649.98
21.52
22,573.80
13.82
3,977
-0.19
69.99
1,920.30
87,699.23
27.52
22,192.10
#1 19.94
3,024
#1 112.49
53.08
33,950.00
72,141.38
51.77
6,409.15
10.80
1,417
27.83
64.97
1,136.00
65,979.06
19.91
31,378.10
17.55
3,366
-0.50
63.70
Forecast
Actual
Growth Rate
Revenue Growth
0.89 %
Net Income Growth
-12.28 %
Cash Flow Change
-48.72 %
ROE
-17.49 %
ROCE
-14.12 %
EBITDA Margin (Avg.)
-7.03 %

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
4,411
4,902
6,159
6,786
8,038
8,536
10,774
13,375
14,439
15,470
16,932
Fixed Assets
1,309
1,439
1,559
1,996
2,088
2,782
3,704
4,325
4,722
4,739
6,464
Current Assets
2,772
3,027
4,011
4,535
4,650
4,680
6,175
8,352
9,312
9,675
10,081
Capital Work in Progress
218
264
444
120
492
920
711
470
212
778
1,022
Investments
733
803
1,631
1,889
1,946
971
0
72
77
82
3,236
Other Assets
2,151
2,397
2,525
2,781
3,513
3,863
6,360
8,508
9,428
9,871
0
Total Liabilities
4,411
4,902
6,159
6,786
8,038
8,536
10,774
13,375
14,439
15,470
16,932
Current Liabilities
776
520
660
653
847
927
1,113
1,196
1,101
1,278
1,452
Non Current Liabilities
141
89
142
208
234
299
367
451
571
621
511
Total Equity
3,495
4,293
5,357
5,925
6,957
7,310
9,295
11,728
12,767
13,571
14,969
Reserve & Surplus
3,469
4,240
5,304
5,872
6,904
7,257
9,242
11,675
12,714
13,518
14,916
Share Capital
27
53
53
53
53
53
53
53
53
53
53

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
3
0
13
-17
23
41
1,987
-816
-1,045
193
Investing Activities
-521
-406
-1,140
-478
-685
-84
75
-2,195
-2,707
-269
Operating Activities
826
1,038
1,150
776
954
1,216
1,947
1,912
2,459
1,261
Financing Activities
-303
-631
2
-314
-246
-1,091
-35
-532
-797
-799

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
51.95 %
51.95 %
51.95 %
51.95 %
51.94 %
51.94 %
51.94 %
51.94 %
51.94 %
51.93 %
51.93 %
51.92 %
51.92 %
51.90 %
51.89 %
51.89 %
51.89 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
14.86 %
14.68 %
16.16 %
17.25 %
17.99 %
18.01 %
DIIs
12.64 %
12.61 %
12.64 %
13.40 %
13.73 %
13.93 %
19.54 %
20.67 %
21.07 %
21.23 %
20.97 %
21.88 %
22.21 %
21.77 %
21.06 %
20.54 %
20.71 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
9.28 %
8.81 %
8.87 %
9.01 %
9.27 %
9.53 %
9.20 %
9.53 %
9.61 %
9.28 %
9.02 %
8.85 %
8.69 %
7.77 %
7.41 %
7.32 %
7.17 %
Others
26.14 %
26.64 %
26.55 %
25.64 %
25.06 %
24.59 %
19.31 %
17.86 %
17.37 %
17.56 %
18.08 %
2.48 %
2.50 %
2.41 %
2.39 %
2.26 %
2.22 %
No of Share Holders
2,08,203
1,93,883
2,23,403
2,74,505
3,09,397
3,46,905
3,79,257
4,14,847
4,33,621
4,02,155
3,73,860
3,54,482
3,47,629
2,98,310
2,78,899
2,80,601
2,67,755

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 10 10 16 16 20 30 30 30 0.00
Dividend Yield (%) 0.00 0.92 0.59 0.8 0.44 0.45 1.06 0.87 0.52 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
11 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
11 Aug 2025 6,281.35 6,883.00
25 Jul 2025 DIVIDEND Dividend
₹ 30.00 /share
25 Jul 2025 6,281.35 6,883.00
17 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
17 May 2025 5,958.35 6,281.35
03 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
03 Feb 2025 5,846.55 5,889.30
09 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
09 Nov 2024 5,802.00 5,938.15
12 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
12 Aug 2024 4,122.75 4,892.85
02 Aug 2024 DIVIDEND Dividend
₹ 30.00 /share
02 Aug 2024 4,122.75 4,990.35
11 Aug 2023 DIVIDEND Dividend
₹ 30.00 /share
11 Aug 2023 3,097.75 3,679.15
12 Aug 2022 DIVIDEND Dividend
₹ 30.00 /share
11 Aug 2022 3,897.90 3,726.20
20 Aug 2021 DIVIDEND Dividend
₹ 20.00 /share
17 Aug 2021 4,120.25 4,818.70
26 Sept 2015 BONUS Bonus
1:1
23 Sept 2015 0.00 0.00

Announcements

Closure of Trading Window8 days ago
Communication To Shareholders - Information Regarding Deduction Of Income Tax At Source From Payment Of Dividend For The Financial Year 2024-25May 29, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 26, 2025
Intimation Of Signing Of Long-Term Manufacturing And Supply AgreementMay 24, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 23, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 19, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 17, 2025
Intimation Of Appointment Of Secretarial AuditorMay 17, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMay 17, 2025
Intimation Of AGM Date And Record Date For DividendMay 17, 2025
Corporate Action-Board approves DividendMay 17, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On May 17 2025May 17, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On May 17 2025May 17, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 16, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 08, 2025
Board Meeting Intimation for Considering And Approving Audited Financial Results For The Quarter And Year Ended March 31 2025 And Recommending Dividend For FY2024-25 If Any.May 08, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementApr 30, 2025
Intimation Of Signing Of Long-Term Manufacturing And Supply AgreementApr 18, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 08, 2025
Closure of Trading WindowMar 31, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMar 31, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 07, 2025
Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotMar 07, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Feb 21, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 07, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 05, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 04, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 04, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 03, 2025
Integrated Filing (Financial)Feb 03, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementFeb 03, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateFeb 03, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On February 03 2025Feb 03, 2025
Outcome Of Board Meeting Held On February 03 2025 - Financial Results For The Quarter And Nine Months Ended December 30 2024Feb 03, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 28, 2025
Board Meeting Intimation for Intimation Of Board MeetingJan 23, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 13, 2025
Initmation Of Commencement Of Commercial Operations At Unit III Greenfield Project At Kakinada Andhra Pradesh In Phased MannerJan 02, 2025
Closure of Trading WindowDec 31, 2024
Resubmission - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements), Regulations, 2015Dec 05, 2024
Clarification /Confirmation On News Item Appearing In 'Media/Publication' Under Regulation 30 Of SEBI (LODR) Regulations, 2015Dec 05, 2024
Intimation Of Action(S) Taken Or Orders PassedDec 04, 2024
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 15, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 11, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 09, 2024
Board Meeting Outcome for Outcome Of Board Meeting - Submission Of Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2024Nov 09, 2024
Submission Of Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2024Nov 09, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 01, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 01, 2024
Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2024.Oct 29, 2024

Technical Indicators

RSI(14)
Neutral
66.85
ATR(14)
Less Volatile
123.46
STOCH(9,6)
Overbought
91.12
STOCH RSI(14)
Overbought
97.06
MACD(12,26)
Bullish
16.22
ADX(14)
Strong Trend
26.76
UO(9)
Bearish
66.69
ROC(12)
Uptrend And Accelerating
6.09
WillR(14)
Overbought
-11.54

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
SBI Equity Hybrid Fund Direct Plan-Growth
0.00%
-3900000
-3.41%
-3.41%
SBI Large Cap Direct Plan-Growth
0.00%
-2731710
-3.46%
-3.26%
SBI Focused Fund Direct Plan-Growth
0.00%
-1900000
-3.38%
-3.63%
Nippon India Pharma Fund Direct-Growth
0.00%
-1198808
-9.49%
-9.57%
Axis ELSS Tax Saver Direct Plan-Growth
0.00%
-1131890
-2.12%
-2.04%
SBI Multicap Fund Direct - Growth
0.00%
-1010000
-3.25%
-3.06%
Axis Focused Direct Plan-Growth
0.00%
-983954
-5.15%
-4.73%
HDFC Balanced Advantage Fund Direct-Growth
0.00%
-888857
-0.59%
-0.51%
SBI Large & Midcap Fund Direct Plan-Growth
0.00%
-830000
-1.75%
-1.68%
Nippon India Large Cap Fund Direct-Growth
0.00%
-799740
-1.27%
-1.23%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth
0.00%
-752472
-9.03%
-7.81%
HDFC Manufacturing Fund Direct - Growth
0.00%
-600000
-3.28%
-3.12%
360 ONE Focused Fund Direct-Growth
0.00%
-496387
-4.44%
-4.34%
SBI Innovative Opportunities Fund Direct-Growth
0.00%
-486563
-4.37%
0.00%
SBI MNC Direct Plan-Growth
0.00%
-482222
-5.01%
-4.68%
Kotak Arbitrage Fund Direct-Growth
0.00%
-473300
-0.46%
-0.84%
Axis Large Cap Fund Direct-Growth
0.00%
-469623
-0.93%
-0.58%
SBI Healthcare Opportunities Fund Direct Plan-Growth
0.00%
-412222
-7.39%
-6.63%
ICICI Prudential Nifty Next 50 Index Direct-Growth
0.00%
-405439
-3.58%
-3.42%
Nippon India Multi Cap Fund Direct-Growth
0.00%
-398947
-0.61%
-0.60%
SBI Arbitrage Opportunities Fund Direct-Growth
0.00%
-354800
-0.69%
-0.57%
Invesco India Contra Fund Direct-Growth
0.00%
-348018
-1.25%
-1.17%
Axis Large & Mid Cap Fund Direct-Growth
0.00%
-321358
-1.48%
-1.51%
Mirae Asset Healthcare Fund Direct - Growth
0.00%
-311280
-7.65%
-7.06%
Mahindra Manulife Multi Cap Fund Direct - Growth
0.00%
-287000
-3.51%
-3.43%

About Divis Laboratories

Divi's Laboratories Ltd is a leading pharmaceutical company specializing in the manufacture of Active Pharmaceutical Ingredients (APIs), Intermediates, and Nutraceuticals. The company operates globally with a presence in over 100 countries and has six manufacturing facilities. It offers both generic and custom synthesis services for pharmaceutical companies, supporting product development from clinical trials to market launch. Divi's Laboratories has two main subsidiaries: Divis Laboratories (USA) Inc. and Divi's Laboratories Europe AG, which focus on marketing nutraceutical products. The company has research centers in Hyderabad and at its manufacturing sites, with a focus on custom synthesis and contract research. Divi's Laboratories has expanded its operations over the years, establishing multiple manufacturing units, including special economic zones (SEZs), and has undergone various regulatory inspections and certifications. The company continues to invest in capacity expansion and infrastructure upgrades to meet growing market demands.
Listing Date
12 Mar, 2003(22 Years, -4 days)
Chairperson NameRamesh B V Nimmagadda